PIPELINE
InnoCure is developing highly differentiated molecules for the treatment of cancer and rare diseases.
We have created a balanced portfolio of traditionally undruggable targets.
| Modality | Program | Indication | Discovery | Lead Optimization | IND Enabling | Phase l |
|---|---|---|---|---|---|---|
| PROTAC / MILPROTAC |
ICTP - 101 | NSCLC, GC, Multiple | ||||
| ICTP - 201 | NMC, T-ALL, Advanced solid tumors | |||||
| ICTP - 301 | Advanced solid tumor | |||||
| ICTP - 401 | Pancreatic cancer | |||||
| AUPTAC (Bivalent Degrader) |
ICTP - 501 | Multiple |